M. Piccart

1.2k total citations
38 papers, 889 citations indexed

About

M. Piccart is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M. Piccart has authored 38 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 19 papers in Cancer Research. Recurrent topics in M. Piccart's work include Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (13 papers) and Advanced Breast Cancer Therapies (12 papers). M. Piccart is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (13 papers) and Advanced Breast Cancer Therapies (12 papers). M. Piccart collaborates with scholars based in Belgium, France and United States. M. Piccart's co-authors include P.F. Bruning, Fátima Cardoso, Tanja Čufer, L. Mauriac, G. Atalay, Laura Biganzoli, Ahmad Awada, Robert E. Coleman, Anne Hamilton and Hervé Bonnefoi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

M. Piccart

35 papers receiving 862 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Piccart Belgium	13	681	409	163	154	90	38	889
Hidemi Kawajiri Japan	15	519 0.8×	259 0.6×	165 1.0×	253 1.6×	139 1.5×	67	857
Yoshiaki Rai Japan	21	827 1.2×	421 1.0×	310 1.9×	193 1.3×	164 1.8×	55	1.2k
R.K. Gregory United Kingdom	13	564 0.8×	410 1.0×	116 0.7×	208 1.4×	132 1.5×	19	874
Yoshiya Horimoto Japan	20	694 1.0×	378 0.9×	235 1.4×	495 3.2×	154 1.7×	97	1.2k
S. Johnston United Kingdom	9	433 0.6×	332 0.8×	231 1.4×	341 2.2×	108 1.2×	17	783
In Ae Park South Korea	12	319 0.5×	241 0.6×	88 0.5×	186 1.2×	93 1.0×	18	605
B. Salvadori Italy	14	547 0.8×	340 0.8×	166 1.0×	115 0.7×	89 1.0×	39	766
E. Magherini France	12	788 1.2×	409 1.0×	260 1.6×	154 1.0×	145 1.6×	24	1.0k
Alessandra Balduzzi Italy	18	710 1.0×	626 1.5×	169 1.0×	247 1.6×	172 1.9×	35	1.0k
S. Johnston United Kingdom	18	508 0.7×	262 0.6×	212 1.3×	265 1.7×	75 0.8×	50	923

Countries citing papers authored by M. Piccart

Since Specialization

Citations

This map shows the geographic impact of M. Piccart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Piccart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Piccart more than expected).

Fields of papers citing papers by M. Piccart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Piccart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Piccart. The network helps show where M. Piccart may publish in the future.

Co-authorship network of co-authors of M. Piccart

This figure shows the co-authorship network connecting the top 25 collaborators of M. Piccart. A scholar is included among the top collaborators of M. Piccart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Piccart. M. Piccart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caluwé, Alex De, Isabelle Desmoulins, Vincent Remouchamps, et al.. (2024). LBA10 Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC). Annals of Oncology. 35. S1205–S1205. 3 indexed citations

Eiger, Daniel, Christian Maurer, Mariana Brandão, et al.. (2020). 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Annals of Oncology. 31. S386–S387. 8 indexed citations

Loi, Sherene, Damien Drubay, Sylvia Adams, et al.. (2016). Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy. Cancer Research. 76(4_Supplement). S1–3. 27 indexed citations

Perez, EA, Eileen Holmes, Evandro de Azambuja, et al.. (2014). Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc). Annals of Oncology. 25. v1–v1. 2 indexed citations

Piccart, M., Hope S. Rugo, Mario Campone, et al.. (2013). Assessment of Genetic Alterations in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer from the BOLERO-2 Trial by Next-Generation Sequencing. Annals of Oncology. 24. iii25–iii25. 8 indexed citations

Rugo, H. S., K.I. Pritchard, Michael Gnant, et al.. (2012). 253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial. European Journal of Cancer. 48. S116–S116. 8 indexed citations

Azambuja, Evandro de, Marc Lemort, José Roberto Freitas Rossari, et al.. (2011). Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172).. Journal of Clinical Oncology. 29(15_suppl). 570–570. 7 indexed citations

Awada, Ahmad, Igor Bondarenko, Jacques Bonneterre, et al.. (2011). P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC).. Cancer Research. 71(24_Supplement). P3–17. 2 indexed citations

Bédard, Philippe L., Michail Ignatiadis, Benjamin Haibe‐Kains, et al.. (2009). Limited Clinical Utility of Prognostic Gene Expression Profiles in Grade 3 Node-Negative Early Stage Breast Cancer.. Cancer Research. 69(24_Supplement). 103–103. 3 indexed citations

10.

Leo, Angelo Di, Minna Tanner, Christine Desmedt, et al.. (2007). p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Annals of Oncology. 18(6). 997–1003. 49 indexed citations

11.

Coleman, Robert E., Laura Biganzoli, Peter Canney, et al.. (2006). A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). European Journal of Cancer. 42(7). 882–887. 67 indexed citations

12.

Bernard-Marty, Chantal, Gaston Demonty, Nicola Personeni, et al.. (2006). Capecitabine as adjuvant therapy for elderly breast cancer (BC) patients (pts): a pilot study. European Journal of Cancer Supplements. 4(2). 154–154.

13.

Ng, Chaan S., Peter Ang, Adam Brufsky, et al.. (2005). Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer. 9 indexed citations

14.

Atalay, G., Fátima Cardoso, Ahmad Awada, & M. Piccart. (2003). Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Annals of Oncology. 14(9). 1346–1363. 87 indexed citations

15.

Therasse, P., L. Mauriac, Marzena Wełnicka-Jaśkiewicz, et al.. (2003). Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study. Journal of Clinical Oncology. 21(5). 843–850. 153 indexed citations

16.

Bonnefoi, Hervé, P. Therasse, Anne Hamilton, et al.. (2003). Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?. Annals of Oncology. 14(3). 406–413. 59 indexed citations

17.

Piccart, M., Fátima Cardoso, & G. Atalay. (2002). Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer. European Journal of Cancer. 38. 52–54. 3 indexed citations

18.

Piccart, M., P.F. Bruning, RE Coleman, et al.. (2000). AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282). Ghent University Academic Bibliography (Ghent University). 13 indexed citations

19.

Mauriac, L., Corinne Veyret, J. Wildiers, et al.. (1998). Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881. Ghent University Academic Bibliography (Ghent University). 8 indexed citations

20.

Peereboom, David M., Ross C. Donehower, E. Eisenhauer, et al.. (1993). Successful re-treatment with taxol after major hypersensitivity reactions.. Journal of Clinical Oncology. 11(5). 885–890. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact